In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed an iteration of CAR-T cell ...

The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI-01, while building the next generation of genomic medicines to address ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3 rd line and later setting at the American Society of Hematology 2024 ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...